



Tumor-Targeting Radioligands for Molecular Imaging and Therapy

Guest Editors:

Dr. Petra Kolenc

Department of Nuclear Medicine,
University Medical Centre
Ljubljana, 1000 Ljubljana,
Slovenia

Dr. Rosalba Mansi

Division of Radiopharmaceutical
Chemistry, Clinic of Radiology
and Nuclear Medicine, University
Hospital Basel, University of
Basel, 4031 Basel, Switzerland

Dr. Marko Krošelj

Department of Nuclear Medicine,
University Medical Centre
Ljubljana, Zaloška 7, 1000
Ljubljana, Slovenia

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editors

Cancer is one of the leading causes of death worldwide. Timely diagnosis of the disease is of utmost importance to support informed decision making and to improve therapy efficacy. Radiopharmaceuticals are vital components of nuclear medicine encompassing such diagnostic methods as single-photon emission computed tomography (SPECT) or positron emission tomography (PET). The increasing development and successful clinical translation of novel radiopharmaceuticals for cancer therapy, such as [^{177}Lu]Lu-DOTATATE and [^{177}Lu]Lu-PSMA-617 paved the way for new and exciting research in the field of nuclear medicine.

This Special Issue titled “Tumor-Targeting Radioligands for Molecular Imaging and Therapy” aims to provide the most recent developments and quests for novel ideal radiopharmaceutical for successful diagnosis, therapy or even theranostics of various tumors. You are kindly invited to contribute either with original article or a review.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com